Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 6/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51876 | 0.77 | — | — | |
| SCHEMBL51652 | 0.68 | OGFRL1 (0.33) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL12225747 | 0.64 | ADORA2A (0.41) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL61820 | 0.64 | OGFRL1 (0.37) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL62910 | 0.63 | OGFRL1 (0.35) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL51828 | 0.62 | SMN1; SMN2 (0.37) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL51875 | 0.61 | CHRNB2 (0.34) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL62081 | 0.61 | CHRNB2 (0.34) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL51443 | 0.61 | CHRNB2 (0.47) | — | |
| SCHEMBL2961593 | 0.60 | TDP2 (0.39) | OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2280981-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | OGFRL1 3981/4885OPRM1 3627/4885OPRK1 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.